1.345

3.46% 0.045

After Hours: 1.29 -0.055 -4.09%

Zentalis Pharmaceuticals Inc (ZNTL)

Overview News Price History Option Chain Financials Why ZNTL Down? Discussions Forecast

Zentalis Pharmaceuticals Inc stock is traded at $1.345, with a volume of 380.43K. It is up +3.46% in the last 24 hours and down -17.99% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Previous Close:

$1.30

Open:

$1.3

24h Volume:

380.43K

Relative Volume:

0.52

Market Cap:

$97.18M

Revenue:

Net Income/Loss:

$-292.19M

P/E Ratio:

-0.2963

EPS:

-4.54

Net Cash Flow:

$-208.41M

1W Performance:

+1.13%

1M Performance:

-17.99%

6M Performance:

+11.16%

1Y Performance:

-57.70%

1-Day Range:

$1.28

$1.35

1-Week Range:

$1.28

$1.425

52-Week Range:

$1.01

$4.00

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name

Zentalis Pharmaceuticals Inc

Sector

Healthcare (1128)

Industry

Biotechnology (632)

Phone

(858) 263-4333

Address

10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY

Employee

166

Twitter

@ZentalisP

Next Earnings Date

2025-03-26

Latest SEC Filings

ZNTL's Discussions on Twitter

Compare ZNTL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZNTL Zentalis Pharmaceuticals Inc	1.345	93.93M	0	-292.19M	-208.41M	-4.54
VRTX Vertex Pharmaceuticals Inc	426.76	107.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	755.90	77.46B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	436.38	58.90B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	918.92	56.55B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	198.76	42.58B	447.02M	-1.18B	-906.14M	-6.1812

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral
Jun-20-24	Downgrade	UBS	Buy → Neutral
Jun-18-24	Downgrade	Jefferies	Buy → Hold
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight
Oct-07-21	Resumed	Jefferies	Buy
Sep-30-21	Initiated	Stifel	Buy
Sep-29-21	Initiated	Oppenheimer	Outperform
May-21-21	Initiated	UBS	Buy
Jan-20-21	Initiated	Wedbush	Outperform
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight
Aug-27-20	Initiated	H.C. Wainwright	Buy
Apr-28-20	Initiated	Guggenheim	Buy
Apr-28-20	Initiated	Jefferies	Buy
Apr-28-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Initiated	SVB Leerink	Outperform

View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

08:54 AM

Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - Setenews

08:54 AM

03:54 AM

Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Zentalis Pharmaceuticals, Inc. $ZNTL - Defense World

03:54 AM

Nov 19, 2025

What indicators show strength in Zentalis Pharmaceuticals Inc.Portfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com

Nov 19, 2025

Is Zentalis Pharmaceuticals Inc. stock in correction or buying zoneMarket Volume Summary & Free Verified High Yield Trade Plans - newser.com

Nov 19, 2025

Why analysts upgrade Zentalis Pharmaceuticals Inc. stockEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com

Nov 19, 2025

Why Zentalis Pharmaceuticals Inc. stock is in analyst buy zone2025 Analyst Calls & AI Driven Stock Reports - newser.com

Nov 19, 2025

Nov 18, 2025

Is Zentalis Pharmaceuticals Inc. forming a bottoming base2025 Top Decliners & Reliable Price Breakout Alerts - newser.com

Nov 18, 2025

Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha

Nov 18, 2025

Nov 16, 2025

Multi asset correlation models including Zentalis Pharmaceuticals Inc.Earnings Beat & Weekly High Conviction Trade Ideas - newser.com

Nov 16, 2025

How geopolitical tensions affect Zentalis Pharmaceuticals Inc. stockBuy Signal & Momentum Based Trading Ideas - newser.com

Nov 16, 2025

Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - Defense World

Nov 16, 2025

Nov 15, 2025

Can Zentalis Pharmaceuticals Inc. stock reach $100 price target2025 Key Highlights & Weekly High Return Stock Opportunities - newser.com

Nov 15, 2025

Nov 14, 2025

FY2025 Earnings Estimate for ZNTL Issued By Leerink Partnrs - Defense World

Nov 14, 2025

Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo

Nov 14, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Analysts - Defense World

Nov 14, 2025

Nov 13, 2025

Wedbush Reiterates “Neutral” Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World

Nov 13, 2025

Morgan Stanley Maintains Zentalis Pharmaceuticals (ZNTL) Equal-Weight Recommendation - MSN

Nov 13, 2025

Nov 12, 2025

Relative strength of Zentalis Pharmaceuticals Inc. in sector analysisPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com

Nov 12, 2025

ZNTL Stock Update: Morgan Stanley Lowers Price Target by 50% | Z - GuruFocus

Nov 12, 2025

What recovery options are there for Zentalis Pharmaceuticals Inc.2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com

Nov 12, 2025